Abstracts tagged "Practice"

Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Beth Wallace^1,2,3, Paul Lin^2,4, Neil Kamdar^2,4, Mohamed Noureldin^2,3,5, Rodney Hayward^2,3,6, David A. Fox¹, Jeffrey R. Curtis⁷, Kenneth Saag⁸ and Akbar Waljee^2,3,9, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁶Department of Internal Medicine, Division of General Medicine, Michigan Medicine, Ann Arbor, MI, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama, Birmingham, AL, ⁹Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…
Abstract Number: 2163 • 2017 ACR/ARHP Annual Meeting
Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice
Prateek C. Gandiga*¹, Junqian Zhang*², Preethi Thomas¹, Victoria P. Werth^2,3, Sapna Sangani¹, Sharon L. Kolasinski¹ and Michael D. George¹, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Myositis autoantibody testing is now widely commercially available, with an evolving role in routine clinical care. However, the use and performance of commercial "myositis…
Abstract Number: 102 • 2017 Pediatric Rheumatology Symposium
Duration of High-Dose Aspirin Therapy Does Not Affect Coronary Artery Outcomes in Kawasaki Disease
Karl Migally¹, Elizabeth A. Braunlin¹, Lei Zhang² and Bryce A. Binstadt³, ¹Pediatric Cardiology, University of Minnesota, Minneapolis, MN, ²Clinical and Translational Sciences Institute, University of Minnesota, Minneapolis, MN, ³Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Kawasaki Disease (KD) is an acute vasculitis targeting the coronary arteries. Prompt treatment with intravenous immunoglobulin (IVIg) reduces the occurrence and potentially the progression…
Abstract Number: 142 • 2015 ACR/ARHP Annual Meeting
Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice
Elise Berthet¹, Virginie Moiroud², Marion De Rosa², Martin Soubrier³ and Sylvain Mathieu⁴, ¹Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ²Médecine Générale, CHU Gabriel Montpied, Clermont-Ferrand, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Chronic inflammatory arthritis affects around 1% of the general population. Disease-modifying drugs like methotrexate (MTX) and in second-line anti tumor necrosis factor (anti-TNF) therapy…
Abstract Number: 2511 • 2015 ACR/ARHP Annual Meeting
Primary Care Management of Patients with Rheumatic Diseases Prior to Rheumatologist Consultation
Jessica Widdifield¹, J Carter Thorne², Karen Tu³, Debra Butt³, Noah Ivers⁴, Claire Bombardier⁴, R. Liisa Jaakkimainen⁵, Vandana Ahluwalia⁶, J. Michael Paterson⁷ and Sasha Bernatsky⁸, ¹McGill University, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Preventive Med and Biostatisti, University of Toronto, Toronto, ON, Canada, ⁶Past President, Ontario Rheumatology Association, Brampton, ON, Canada, ⁷ICES, Toronto, ON, Canada, ⁸Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Primary care physicians (PCP) often play a central role in the early detection and referral for patients with rheumatic diseases. Our aim was to…
Abstract Number: 2272 • 2014 ACR/ARHP Annual Meeting
Assessment of Transition Readiness in Adolescents and Young Adults with Rheumatic and Other Chronic Health Conditions
Gabrielle Paul¹, Stephanie LaCount², Charles H. Spencer³, Gloria C. Higgins⁴, Karla Jones⁵, Brendan Boyle⁶, Manmohan K. Kamboj⁷, Christopher Smallwood⁸ and Stacy P. Ardoin⁹, ¹College of Medicine, Ohio State University, Columbus, OH, ²Pediatrics, Ohio State University, Columbus, OH, ³Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ⁴Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁵Pediatrics, Nationwide Children's Hospital, Ohio, OH, ⁶Gastroenterology, Nationwide Children's Hospital, Columbus, OH, ⁷Endocrinology, Nationwide Children's Hospital, Columbus, OH, ⁸Family Medicine, Ohio State Univeristy, Columbus, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose The transition from pediatric to adult care is a vulnerable period. The lack of objective measures of transition readiness is a barrier to improving…
Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting
Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Stefan Kleinert¹, Margret Breunig², Hans-Peter Tony³, Martin Feuchtenberger⁴, Marc Schmalzing⁵, Christian Kneitz⁶, Stefanie Lehmann⁷, Christiane Angermann^7,8, Georg Ertl⁸ and Stefan Störk⁷, ¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ²Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].